-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Journal of Clinical Oncology (IF:44.
544), an authoritative journal in the field of cancer treatment worldwide, published an online publication of a field of interventional therapy for advanced liver cancer by Professor Ming Zhao’s team from the Department of Minimally Invasive Interventional Therapy, Center for Cancer Prevention and Treatment, Sun Yat-sen University Phase III clinical study (FOHAIC-1)
.
This study demonstrated for the first time that the interventional technique-based hepatic arterial infusion of oxaliplatin + fluorouracil (HAIC-FO) in the treatment of advanced liver cancer is significantly better than sorafenib targeted therapy in the treatment of advanced liver cancer; at the same time, it is the first time at the genetic level.
The exploration and development of the HAIC-FO curative effect prediction model fills the gap in the field of interventional therapy and molecular model curative effect prediction for advanced liver cancer in China, and provides evidence-based medical evidence for the combined treatment strategy based on hepatic artery infusion chemotherapy
.
This research was independently completed by Sun Yat-sen University Cancer Center.
Professor Ming Zhao is the corresponding author, and deputy chief physician Lv Ning is the first author
.
Professor Ming Zhao took the lead in researching the hepatic artery infusion of oxaliplatin + fluorouracil.
Professor Ming Zhao’s team based on China’s national conditions, took the lead in the world to apply the method of "oxaliplatin combined with fluorouracil (FOLFOX) hepatic artery infusion chemotherapy" to advanced liver cancer In clinical research
.
As early as 2014, the research team began to gradually and systematically explore the clinical safety and technical feasibility of HAIC-FO treatment in clinical practice, and registered in May 2015 to carry out the world’s first phase 2 clinical study—FOXAI study, which was initially confirmed This program has the clinical application value of good safety, less painful treatment and better curative effect
.
The relevant results were published online in June 2017 by the official journal of the British Society of Gastroenterology, the Digestive Tract (Gut)
.
Following the FOXAI study, the research team conducted a retrospective (PSM) comparative analysis between HAIC-FO and sorafenib, the first-line treatment plan at that time, and concluded that the treatment of advanced liver cancer with intrahepatic lesions was effective and survival There may be advantages in benefit, and the results were published in the Journal of Hepatology, the official journal of the European Society of Hepatology
.
The research team registered in May 2017 to carry out a phase 3 randomized controlled clinical study—FOHAIC-1 study
.
After 4 years of painstaking research and exploration, the team of Professor Ming Zhao orally reported the main results of the FOHAIC-1 study at the American Society of Clinical Oncology (ASCO) annual meeting in June 2021, and further published the results online on JCO
.
The study shows a good survival benefit advantage.
The main subjects included in the FOHAIC-1 study are representative and universal people with advanced liver cancer in China-the burden of intrahepatic tumors is severe, and about three-quarters of patients are accompanied by large-vessel tumor thrombi.
Violated
.
The research is closer to China's clinical practice and will help improve the treatment level of advanced liver cancer in China
.
The main results of FOHAIC-1 showed that the median overall survival and progression-free survival in the HAIC-FO group were 13.
9 months and 7.
8 months, respectively; the disease down-stage rate was about 12.
3%, and the preferred treatment after down-stage was local thermal ablation and Hepatic Artery Embolization Chemotherapy (TACE) interventional therapy has a progression-free survival period of 16.
4 months and an overall survival period of 20.
8 months
.
In addition, among the subgroups of people with local high-risk risk factors, the HAIC-FO group also showed the advantage of good survival benefits, with an overall survival period of about 10.
8 months, suggesting that it has competition and combined first-line immunity + anti-angiogenesis/ The potential value of the targeted program (7.
6 months)
.
Professor Ming Zhao’s team FOHAIC-1 opens a new era of hepatocarcinoma gene sequencing curative effect prediction The FOHAIC-1 research team developed and constructed a HAIC-FO curative effect prediction model at the genetic level.
The model is composed of 15 genes with a prediction efficiency of 83% and a moderate number With the characteristics of high accuracy and high accuracy, the survival benefit of the HAIC-FO effective population identified by this model is significantly improved.
The progression-free survival and overall survival are approximately 14.
3 and 19.
3 months, respectively, suggesting that this model is expected to become the first advanced liver cancer.
The HAIC-FO curative effect and survival benefit prediction model promotes the advancement of individualized treatment strategies for advanced liver cancer arterial infusion
.
Based on the research results of Professor Zhao Ming’s team, the Sun Yat-Sen University Cancer Center and other provincial fraternal hospitals have already used the HAIC-FO treatment program in the first-line clinical practice of newly diagnosed advanced liver cancer, and achieved significant social benefits
.
The FOHAIC-1 study confirmed for the first time the value of HAIC-FO interventional therapy in the treatment of advanced liver cancer, and provided clear evidence-based medical evidence for the current clinical use of HAIC-FO in advanced liver cancer in China, and for the further development of interventional HAIC-FO The cornerstone of the cutting-edge exploration of combined immune/targeted system therapy
.
Text/Zhao Ming, Lv Ning Source: Sun Yat-Sen University Cancer Center Contribution Email: tougao@medlive.
cn
544), an authoritative journal in the field of cancer treatment worldwide, published an online publication of a field of interventional therapy for advanced liver cancer by Professor Ming Zhao’s team from the Department of Minimally Invasive Interventional Therapy, Center for Cancer Prevention and Treatment, Sun Yat-sen University Phase III clinical study (FOHAIC-1)
.
This study demonstrated for the first time that the interventional technique-based hepatic arterial infusion of oxaliplatin + fluorouracil (HAIC-FO) in the treatment of advanced liver cancer is significantly better than sorafenib targeted therapy in the treatment of advanced liver cancer; at the same time, it is the first time at the genetic level.
The exploration and development of the HAIC-FO curative effect prediction model fills the gap in the field of interventional therapy and molecular model curative effect prediction for advanced liver cancer in China, and provides evidence-based medical evidence for the combined treatment strategy based on hepatic artery infusion chemotherapy
.
This research was independently completed by Sun Yat-sen University Cancer Center.
Professor Ming Zhao is the corresponding author, and deputy chief physician Lv Ning is the first author
.
Professor Ming Zhao took the lead in researching the hepatic artery infusion of oxaliplatin + fluorouracil.
Professor Ming Zhao’s team based on China’s national conditions, took the lead in the world to apply the method of "oxaliplatin combined with fluorouracil (FOLFOX) hepatic artery infusion chemotherapy" to advanced liver cancer In clinical research
.
As early as 2014, the research team began to gradually and systematically explore the clinical safety and technical feasibility of HAIC-FO treatment in clinical practice, and registered in May 2015 to carry out the world’s first phase 2 clinical study—FOXAI study, which was initially confirmed This program has the clinical application value of good safety, less painful treatment and better curative effect
.
The relevant results were published online in June 2017 by the official journal of the British Society of Gastroenterology, the Digestive Tract (Gut)
.
Following the FOXAI study, the research team conducted a retrospective (PSM) comparative analysis between HAIC-FO and sorafenib, the first-line treatment plan at that time, and concluded that the treatment of advanced liver cancer with intrahepatic lesions was effective and survival There may be advantages in benefit, and the results were published in the Journal of Hepatology, the official journal of the European Society of Hepatology
.
The research team registered in May 2017 to carry out a phase 3 randomized controlled clinical study—FOHAIC-1 study
.
After 4 years of painstaking research and exploration, the team of Professor Ming Zhao orally reported the main results of the FOHAIC-1 study at the American Society of Clinical Oncology (ASCO) annual meeting in June 2021, and further published the results online on JCO
.
The study shows a good survival benefit advantage.
The main subjects included in the FOHAIC-1 study are representative and universal people with advanced liver cancer in China-the burden of intrahepatic tumors is severe, and about three-quarters of patients are accompanied by large-vessel tumor thrombi.
Violated
.
The research is closer to China's clinical practice and will help improve the treatment level of advanced liver cancer in China
.
The main results of FOHAIC-1 showed that the median overall survival and progression-free survival in the HAIC-FO group were 13.
9 months and 7.
8 months, respectively; the disease down-stage rate was about 12.
3%, and the preferred treatment after down-stage was local thermal ablation and Hepatic Artery Embolization Chemotherapy (TACE) interventional therapy has a progression-free survival period of 16.
4 months and an overall survival period of 20.
8 months
.
In addition, among the subgroups of people with local high-risk risk factors, the HAIC-FO group also showed the advantage of good survival benefits, with an overall survival period of about 10.
8 months, suggesting that it has competition and combined first-line immunity + anti-angiogenesis/ The potential value of the targeted program (7.
6 months)
.
Professor Ming Zhao’s team FOHAIC-1 opens a new era of hepatocarcinoma gene sequencing curative effect prediction The FOHAIC-1 research team developed and constructed a HAIC-FO curative effect prediction model at the genetic level.
The model is composed of 15 genes with a prediction efficiency of 83% and a moderate number With the characteristics of high accuracy and high accuracy, the survival benefit of the HAIC-FO effective population identified by this model is significantly improved.
The progression-free survival and overall survival are approximately 14.
3 and 19.
3 months, respectively, suggesting that this model is expected to become the first advanced liver cancer.
The HAIC-FO curative effect and survival benefit prediction model promotes the advancement of individualized treatment strategies for advanced liver cancer arterial infusion
.
Based on the research results of Professor Zhao Ming’s team, the Sun Yat-Sen University Cancer Center and other provincial fraternal hospitals have already used the HAIC-FO treatment program in the first-line clinical practice of newly diagnosed advanced liver cancer, and achieved significant social benefits
.
The FOHAIC-1 study confirmed for the first time the value of HAIC-FO interventional therapy in the treatment of advanced liver cancer, and provided clear evidence-based medical evidence for the current clinical use of HAIC-FO in advanced liver cancer in China, and for the further development of interventional HAIC-FO The cornerstone of the cutting-edge exploration of combined immune/targeted system therapy
.
Text/Zhao Ming, Lv Ning Source: Sun Yat-Sen University Cancer Center Contribution Email: tougao@medlive.
cn
